It is made available under a CC-BY 4.0 International license .

1	<i>CR1</i> variants contribute to FSGS susceptibility across multiple populations.
2 3 4	Rostislav Skitchenko ^{1,2} , Zora Modrusan ³ , Alexander Loboda ^{1,2,4} , Jeffrey B. Kopp ⁵ , Cheryl A. Winkler ⁶ , Alexey Sergushichev ¹ , Namrata Gupta ⁴ , Christine Stevens ⁴ , Mark J. Daly ^{4,7,8} , Andrey Shaw ^{3,#} , Mykyta Artomov ^{4,9,10,#}
5 6 7 8 9	 ¹ – ITMO University, St. Petersburg, Russia ² – Almazov National Medical Research Centre, St. Petersburg, Russia ³ – Research Biology, Genentech Inc., San Francisco, CA, USA ⁴ – Broad Institute, Cambridge, MA, USA
9 10 11 12 13 14 15 16 17 18 19	 ⁵ – Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA ⁶ – Molecular Genetic Epidemiology Studies Section, National Cancer Institute (NCI), Frederick, Maryland, USA ⁷ – Massachusetts General Hospital, Boston, MA, USA ⁸ – Institute for Molecular Medicine Finland, Helsinki, Finland ⁹ – Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, USA ¹⁰ – Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
20 21	# – correspondence: <u>shaw.andrey@gene.com</u> , <u>mykyta.artomov@nationwidechildrens.org</u>
22	
23	A conflict of interest statement is at the end of the manuscript.
24	

It is made available under a CC-BY 4.0 International license .

26 Abstract

27

Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome 28 29 with an annual incidence in the United States in African-Americans compared to European-30 Americans of 24 cases and 5 cases per million, respectively. Among glomerular diseases in 31 Europe and Latin-America, FSGS was the second most frequent diagnosis, and in Asia the fifth. 32 We expand previous efforts in understanding genetics of FSGS by performing a case-control 33 study involving ethnically-diverse groups FSGS cases (726) and a pool of controls (13,994), 34 using panel sequencing of approximately 2,500 podocyte-expressed genes. Through rare variant 35 association tests, we replicated known risk genes - KANK1, COL4A4, and APOL1. A novel 36 significant association was observed for the gene encoding complement receptor 1 (CR1). High-37 risk rare variants in CR1 in the European-American cohort were commonly observed in Latin-38 and African-Americans. Therefore, a combined rare and common variant analysis was used to 39 replicate the CR1 association in non-European populations. The CR1 risk variant, rs17047661, 40 gives rise to the Sl1/Sl2 (R1601G) allele that was previously associated with protection against 41 cerebral malaria. Pleiotropic effects of rs17047661 may explain the difference in allele 42 frequencies across continental ancestries and suggest a possible role for genetically-driven 43 alterations of adaptive immunity in the pathogenesis of FSGS.

It is made available under a CC-BY 4.0 International license .

44 Introduction

Focal segmental glomerulosclerosis (FSGS) is a common cause of primary nephrotic syndrome among both adults and children in the USA, and its incidence is increasing.^{1,2} The incidence and prevalence of FSGS are not precisely known due to the requirement of a kidney biopsy for diagnosis and the lack of a central registry. Estimates for incidence range from 1.4 to 21 cases per million population.³ The incidence of FSGS in the U.S. is about 4 times higher in African Americans (6.8 patients per million) and 2 times higher in Latin-Americans (3.7 patients per million) compared to European-Americans (1.9 patients per million).⁴

52 Genetic studies of FSGS, conducted using both pedigree analyses and cohort-based 53 association studies, have identified a number of susceptibility genes, yet explaining only a 54 fraction of family-history enriched cases.⁵ The first genetic studies identifying the chromosome 55 (chr) 22 region with FSGS were prompted by the observed higher prevalence of FSGS in African 56 and African-American populations, suggesting that one or more FSGS susceptibility gene 57 variants would be enriched on African-derived haplotypes.⁶⁻⁸ The subsequent discovery of 58 association of G1 and G2 coding variants in APOL1 with FSGS provided an explanation for 59 increased prevalence of the disease among African-descent populations. Pleiotropic properties 60 of these variants resulted in protection against trypanosomiasis but at the cost of increased 61 FSGS risk.9

In this study, a large-scale genetic database was assembled from biopsy-confirmed cases of Focal Segmental Glomerulosclerosis (FSGS) and ethnically matched controls. The study used a panel of approximately ~2,500 genes associated with podocytes, which play a crucial role in the formation and maintenance of the glomerular filtration barrier. The purpose of the study was to investigate the genetic basis of FSGS and identify novel susceptibility genes. This study is a significant extension of previous work conducted by Yu et al⁵, with increased power and a more diverse multi-ethnic cohort with greater sample size.

69

It is made available under a CC-BY 4.0 International license .

70

71 Methods

72 DNA samples were obtained from patients participating in a multicenter NIDDK study of 73 biopsy-confirmed FSGS⁶ and from patients diagnosed at Washington University. The research 74 protocols were approved in advance and all subjects provided informed consent or assent. As 75 all samples were de-identified, the Washington University in St. Louis Institutional Review 76 Board (IRB) deemed that these studies did not require IRB approval. A total of 726 samples 77 were collected in a multicenter NIH study of biopsy-confirmed FSGS ⁶ and from patients 78 similarly diagnosed at Washington University, the latter inherited from Yu et al ⁵. Genetic data 79 for cases were obtained using a "podocyte exome" sequencing approach, consisting of a panel of 80 2,482 genes, as described in Yu et al ⁵. Of the selected genes, mutations in five genes cause 81 familial FSGS and 200 genes are functionally related to these five. Additional genes were 82 selected based on expression profiles, as 677 genes are highly expressed in human micro-83 dissected glomeruli, and 1600 genes are human orthologs of highly-expressed mouse podocyte 84 genes (Figure 1A). In the present study using this panel, only the 2,482 genes constituting the 85 "podocyte exome" were analyzed, with 1.12% of the sequencing capture nucleotides located in 86 non-coding DNA.

87 The raw data files with sequencing reads (FASTQ files) were obtained for control 88 subjects from dbGAP general population cohorts not ascertained for kidney disease history 89 (Sup. Table S1). We extracted the regions sequenced in the podocyte exome from the full-90 exome data of the control cohort. There were 333,239 variants in the raw dataset of 726 cases 91 and 13,994 controls. We performed joint variant calling according to GATK best practices,¹⁰ to 92 construct a case-control dataset. To confirm the absence of insufficient coverage biases 93 between cases and controls, we crossed the intervals common to both panels and then we 94 calculated the fraction of sequencing intervals that were well-covered (>10X) in cases and 95 controls; this was found to be 89% for both groups (Figure S1). In this calculation, only

It is made available under a CC-BY 4.0 International license .

96 variants that passed initial GATK hard-filtering¹⁰ were used. Next, the case-control dataset was
97 subjected to quality filtration using the Hail 0.2 open source software library ¹¹ (Figure S2).

98 The final data set included 577 cases (including 179 from Yu et al⁵), (including 378 from 99 Yu et al⁵), and 131,179 variants. The drop-out rate was 60.64% for variants and 6.85% for 100 samples. The high drop-out rate for variants is explained by exome sequencing being joined 101 with panel sequencing in a single dataset, requiring exclusion of many variants detected in the 102 exome sequences of controls and not sequenced in the case panel, due to broader DNA region 103 coverage in controls.

To account for population stratification, a joint principal components analysis (PCA) was performed for case and control genotypes. Uncorrelated common variants (linkage disequilibrium pruning: r²<0.9; minor allele frequency – MAF>0.05) were used to cluster the samples in PCA space. To reduce the risk of false associations in the rare variant analysis due to population stratification, we used principal components to subset the control cohort to match the genetic background of cases.

110 First, we partitioned the dataset into clusters representing global population groups. 111 Clustering was performed using mixed Gaussian models AutoGMM package¹². The data were 112 stratified into eight clusters according to the Gaussian mixture model. Agnostic clusters 113 modeled by the AutoGMM algorithm were mapped to known clusters of the 1000 Genomes 114 Project and labeled accordingly (Figure S3). Two minor clusters of individuals belonging to 115 South Asian and East Asian populations and admixed ancestry were excluded from the analysis 116 due to small case count in each cluster, resulting in low statistical power. Of the six clusters 117 retained for further study, three included individuals of European descent and reflected 118 different local-population origins; these minor-clusters were combined into a single major-119 European cluster. The fourth cluster represented the individuals with African ancestry. Two 120 other clusters belonged to the Latin-American population. After filtering out the low power 121 clusters, the dataset had 551 cases and 11,591 controls (Figure S4).

It is made available under a CC-BY 4.0 International license .

122 Further case-control matching was conducted using the Matchlt¹³ package (Figure 1B, 123 Figure S4). 16 cases were excluded from further consideration because it was not possible to 124 select appropriate population controls for them. The final dataset included 358 cases and 1,488 125 controls for the European-American cluster, 125 cases and 137 controls for the African-126 American cluster and 52 cases and 288 controls for the Latin-American cluster (Figure S4). The 127 Weir and Cockerham F-statistic for analysis of population structure showed that the European-128 American cluster and the African-American cluster were sufficiently isolated from each other 129 (weighted mean fixation index Fst=0.0878 for case cohorts), demonstrating distinct population 130 differences. The Latin-American cluster is also sufficiently isolated from the other clusters 131 (weighted mean fixation index Fst=0.0148). The power analysis for the European-American 132 dataset showed many-fold power superiority over previous FSGS cohort studies ¹⁴, and that an 133 exponential power increase threshold has been reached with the current number of cases, *i.e.*, a 134 significant power increase could not be achieved with a larger number of controls (Figure S5). 135 The values of significant power for the African and Latin-American clusters are comparable to 136 those of similar studies on European cohorts, but they may not be sufficient to detect genome-137 wide significant associations of frequent variants because of their small effect size (Figure S6).

We performed an association study using common synonymous variants (gnomAD population specific $AF \ge 0.01$), as these are unlikely to contribute to a phenotype and yet reflect possible ancestral bias between case and matched controls cohorts. For all three European-American, African-American and Latin-American post-matching datasets we confirmed the absence of systematic bias between cases and controls (**Figure 1C**).

143 Results

Using a data set of matched cases and controls after quality filtration, we performed
several association studies. Because analyses of this dataset were limited to the "podocyte
exome", we focused on missense variants and protein truncation variants (PTV).

It is made available under a CC-BY 4.0 International license .

147 For each cluster separately, we conducted a variant-based association study using linear 148 regression with no additional covariates. 3,777 variants with missense and PTV (stop_gained, 149 frameshift_variant, splice_acceptor_variant, splice_donor_variant) effects on protein were 150 included in this analysis. In the European-American cluster, two variants were significantly 151 associated with FSGS: (1) rs601314 - $p=8.1x10^{-9}$, reference allele is a minor allele; 152 (CI_{95%}=[3.996, 56.51]), missense, *EFEMP2* (EGF-containing fibulin OR_{minor allele}=13.24 153 extracellular matrix protein 2); and (2) $rs117071588 - p=4.0x10^{-6}$, alternative allele is a minor 154 allele; ORminorallele=11.66 (CI95%=[2.790, 68.35]), missense, CCDC82 (coiled-coiled domain 155 containing 82), Significance threshold was determined with Bonferroni correction -156 p<0.05/3,777=1.32x10⁻⁵; Figure S7, Sup. Table S2). Replication analysis of these two variants 157 in the African-American cohort showed that the rs601314 variant (EFFMP2) was not 158 significantly associated with FSGS (p=0.062, reference allele is a minor allele, 159 $OR_{minorallele}=0.7418$, $Cl_{95\%}=[0.5370, 1.015]$ and that rs117071588 (*CCDC82*) was absent from 160 the African-American dataset. A similar situation was observed when replication was attempted 161 in the Latin-American cohort: rs601314 was not significantly associated (p=0.097, reference 162 allele is a minor allele, OR_{minor allele}=2.99, Cl_{95%}=[0.6891, 14.76]), rs117071588 was absent from 163 the data. Despite the significant association statistics of *EFEMP2* and *CCDC82* in the European-164 American group, the lack of replication of the EFEMP2 variant FSGS association in the other 165 populations makes this a less robust finding but might serve as a starting point for future 166 studies.

The rs601314 in *EFEMP2* (NC_000011.9:g.65636053T>C, ENSP00000434151:p.I259V)
and rs117071588 in *CCDC82* (NC_000011.9:g.96117537A>C, ENSP00000278520:p.D125E)
variants are defined by most common *in silico* pathogenicity predictors as benign ¹⁵. FATHMM
classified rs601314 as "damaging" (Fathmm Score Converted = 0.48) ¹⁵. The specific predictors
of missense deleteriousness classified rs601314 and rs117071588 as benign (MISTIC<0.5) ¹⁶.
Variant rs601314 affects the von Willebrand factor type A (vWA) domain of *EFFMP2* and
variant rs117071588 affects the domain of unknown function (DUF4196) of *CCDC82* ¹⁵. Both

It is made available under a CC-BY 4.0 International license .

variants have a missense effect on protein function and come from non conservative parts of
proteins (MPC<2.0)¹⁷.

176 We carried out rare variant burden analyses in the European-American cohort, focusing 177 on missense variants and PTV with a population frequency below 0.01. This cutoff was chosen 178 according to the presence of a signal in each of the quartiles of allele frequency distribution in 179 the interval [0, 0.01] (Figure S8). A rare variant association study (RVAS) was performed using 180 five tests representing different statistical classes of methods for each gene, in order to identify 181 all potential risk patterns. If most variants are causal and have unidirectional effects, classical 182 burden tests are useful, due to their high power. However, adaptive burden tests are considered 183 more reliable than those using fixed weights or thresholds. ¹⁸ In addition, some tests can 184 improve understanding of the results. Tests of variance components are effective when there 185 are variants that both increase and decrease a trait, or have a limited number of causal variants 186 ¹⁸. These tests included Fisher's exact test, C-alpha, adaptive sum statistic (ASUM), weighted 187 sum statistics (WSS) and kernel-based adaptive clustering (KBAC) (Figure S9). The resulting p-188 values were combined using the Simes method for multiple hypothesis testing, which is suitable 189 for merging dependent test statistics (Sup. Table S3). The top 10 associated genes included 190 four genes, APOL1, KANK1, COL4A4, IL36G, that were previously identified in FSGS association 191 studies. Of these, the top two genes reached significance after Bonferroni correction 192 (p=0.05/2,482=2.015x10⁻⁵): APOL1 (p=1.47x10⁻⁶), a known FSGS susceptibility gene, and CR1 193 (p=1.67x10⁻⁵), a novel candidate gene (**Figure 2A, Sup. Figure S10**).

Significantly-associated genes in the European-American cohort were further examined in a replication study of the African-American and Latin-American cohorts. Neither *APOL1* nor *CR1* were replicated using rare (MAF<0.01) variant analysis (**Sup. Table S4**). Previouslyobserved positive selection acting on the *APOL1*⁹ variants in the African-American population suggests that FSGS risk variants might be too common to be detected by a RVAS in non-European populations. Therefore, we used the variant-based tests to replicate the FSGSassociation signals in *APOL1* and *CR1*.

It is made available under a CC-BY 4.0 International license .

201 We identified rare variants in the European-American cohort that drove the association 202 signals in APOL1 and CR1 and four variants, consisting of pair-locus G1 in APOL1 (rs60910145 203 [NC 000022.10:g.36662034T>G, ENSP00000317674.4 p lle400Met] and rs73885319 204 [NC_000022.10:g.36661906A>G, ENSP00000317674.4:p.Ser358Gly]⁹) and two closely-adjacent 205 CR1 [NC_000001.10:g.207782889A>G, variants in (rs17047661 206 and rs17047660 ENSP000003560164;p.Arg2051Glv] [NC 000001 10 g 207782856A>G 207 ENSP00000356016.4:p.Lys2040Glu]) were selected for replication in other ancestries 208 (Figure 2B). Additionally, we eliminated the possibility of this result being a false positive due 209 to coverage imbalance in the associated genes (Sup. Figure S11). APOL1 variants were 210 successfully replicated (rs73885319: p=0.001779, alternative allele is a minor allele, 211 OR_{minorallele}=1.59, Cl_{95%}=[1.18, 2.14]; rs60910145: p=0.002271, alternative allele is a minor 212 allele, OR_{minorallele}=1.58, CI_{95%}=[1.17, 2.12]). The variants in CR1 were more common and had 213 smaller effect size, therefore, we lacked the statistical power to see the significant replication 214 (rs17047661: p=0.28, reference allele is a minor allele, OR_{minor allele}=1.22, CI_{95%}=[0.84, 1.76]; 215 rs17047660: p=0.74, alternative allele is a minor allele, OR_{minor allele}=1.09, CI_{95%}=[0.69, 1.71]).

Second replication was attempted in the Latin-American cohort because the variant frequencies for the variants of interest are more similar to the original European-American cohort. Variants rs17047661 in *CR1* and rs60910145 and rs73885319 in *APOL1* surpassed the replication significance threshold (p=0.05/4=0.0125) (**Sup. Table S5**). Analysis of the statistical power for identified effect sizes in Latin-American and African-American cohorts indicated that the lack of replication in the latter is most likely driven by the statistical power limitations (**Sup. Figure S6**).

223 Meta-estimates of pMETAL ¹⁸ for all 4 variants were also calculated for the European-224 American and Latin-American cohorts: rs60910145 ($p_{METAL}=9.706x10^{-6}$), rs73885319 225 ($p_{METAL}=1.420x10^{-4}$), rs17047660 ($p_{METAL}=0.6359$), rs17047661 ($p_{METAL}=9.314x10^{-3}$). 226 Interestingly, the variants in *CR1*: rs17047661 and rs17047660 are linked with only three out 227 of four possible haplotypes observed in African subpopulations in 1000 genomes

It is made available under a CC-BY 4.0 International license .

228 (AFR:YRI+LWK+GWD+MSL+ESN+ASW+ACB: $r^2=0.15$, D'=1; YRI: $r^2=0.15$, D'=1; 229 ASW: $r^2=0.18$, D'=1; ACB: $r^2=0.13$, D'=1) and observed in global Latin-American population 230 (AMR:MXL+PUR+CLM+PEL: $r^2=0.46$, D'=1).

Next, the normalized integral haplotype score (iHS) was directly estimated in the discovery cohort for the variants included in the replication analysis. For the African American cohort, selection pressure analysis confirmed positive selection (iHS<-2.0) for the G1 APOL1 alleles: rs73885319 (iHS=-2.16), rs60910145 (iHS=-2.21) and revealed positive selection for rs17047660 (iHS=-2.71) in CR1, whereas no such selection was detected for rs17047661 (iHS=-1.04). The following results were obtained for the Latin American cohort: rs73885319 (iHS=-1.99), rs60910145 (iHS=-2.01), rs17047660 (iHS=-0.142) and rs17047661 iHS=1.13).

238 Allele frequencies for all variants included in the replication analyses are significantly 239 different between population groups, which can nominally indicate either positive selection or 240 genetic drift. These included the following variants: rs60910145: gnomAD EUR AF=8.6x10⁻⁵, 241 gnomAD AFR AF=0.23, $p=2.2x10^{-16};$ rs73885319: gnomAD EUR AF=1.1x10⁻⁴, 242 gnomAD AFR AF=0.23 $p=2.2x10^{-16}$ rs17047661: gnomAD EUR AF= $3.0x10^{-3}$. 243 gnomAD AFR AF=0.62, $p=2.2x10^{-16};$ and rs17047660: gnomAD EUR AF= 1.0×10^{-3} , 244 gnomAD AFR AF=0.24, p= 2.2×10^{-16}). It is likely that iHS estimates can be skewed by complex 245 population structure or demographic variables such as population growth, bottleneck events, 246 and changes in recombination and mutation frequencies. Notably, the allele frequencies within 247 African and African-American populations in 1000 genomes significantly vary for 248 rs17047661 (AFyri=0.69, AFLWK=0.70, AFGWD=0.79, AFMSL=0.79, AFESN=0.72, AFASW=0.58, 249 AF_{ACB}=0.66).

We sought evidence of co-evolving changes in allele frequencies between (a) the G1 and G2 variants in *APOL1* and (b) replicated rs17047661 in *CR1*. We estimated the number of individuals who carry both rs17047661 and either one or both G1 and G2 alleles in the African-American case cohort and compared this with the expectation of random assortment. There

It is made available under a CC-BY 4.0 International license .

were no signs of linkage between these variants (p=0.93, binomial test), which suggests that the
effects of rs17047661 are fully independent of those of *APOL1*.

256 Most common in silico variant effect predictors do not categorize rs17047661 257 (NC_000001.10:g.207782889A>G, ENSP00000383744:p.R1601G) as pathogenic ¹⁵. Exceptions 258 are, for example, PolyPhen2 HVAR and MutationAssessor, which classify rs17047661 as "probably damaging" (Polyphen 2 Hvar Score = 0.964) and "medium functional effect" 259 260 (Mutationassessor Score Converted = 0.70), respectively ¹⁵. The rs17047661 variant of CR1 261 induces a missense effect (p.R1601G) in the protein domains common to secreted complement 262 fixation protein (PHA02927) and complement control protein (CCP) modules, also known as 263 consensus short repeats (SCR) or SUSHI repeats. Specifically, it affects the one of the four Long 264 Homologous Repeats (LHRs), LHR-D, which is responsible for binding C1q, Mannose Binding 265 lectin (MBL) and ficolin ^{15,19}. However, the specific predictors of missense deleteriousness 266 classified rs17047661 as benign (MISTIC<0.5) ¹⁶, which is likely due to the nonconservative 267 nature of the affected region (MPC<2.0) ¹⁷.

268

269 Discussion

270 The complement system is a complex network of proteins that play an important role in 271 protecting the body against microbial infections, which are activated either through the 272 classical immune pathway in response to binding to Fc-fragments of IgM or IgG, or through an 273 alternative pathway of non-specific binding to antigens on membranes or to mannose residues 274 through the lectin pathway.²⁰ Each protein in the cascade is activated by proteolysis, splitting 275 the original proenzyme into "a" and "b" structures (the exception is C1, which splits into q, r, s 276 molecules). The large molecule "b" is directly involved in the sequential activation of the 277 complement system and the small molecule "a" is an anaphylatoxin, which causes degranulation 278 of mast cells and chemotaxis of other immune cells such as neutrophils, eosinophils, monocytes, 279 and T lymphocytes. All of these factors have the potential to contribute to either innate immune

It is made available under a CC-BY 4.0 International license .

280 functions or tissue injury. C3 is the central element of the complement system, which is 281 activated by C3-convertase, a complex composed of the preceding elements of the cascade 282 (classical/lectin pathway: C4bC2b complex, alternative pathway: C3bBb complex). Upon 283 activation, the complement system can affect cells in two ways: (1) by forming the membrane 284 attack complex (MAC, sC5b-9 complex), resulting in osmotic lysis of the targeted cell, and (2) 285 indirect opsonization through the deposition of C3b on the surface of microbes, which 286 facilitates phagocytosis by immune cells.

287 CR1 acts as a negative complement regulator, reducing C3 activation and tissue 288 deposition, by processing and bounding immune complexes, which then facilitates their 289 transfer to the liver or spleen where macrophages ingest and eliminate them. In both the 290 classical and lectin pathways, CR1 has decay-activating activity, in that its binding C4b prevents 291 the formation of C3-convertase. In the alternative pathway, CR1 then acts as a cofactor for the 292 cleavage of active C3b fragments (on C3c and C3dg fragments), significantly reducing 293 deposition of C3b fragments, which could activate C3.²¹ CR1 significantly reduces C3b 294 deposition by $\sim 80\%$ over the classical pathway, but CR1 is most potent when the alternative 295 pathway is activated (> 95% reduction in C3b deposition).²¹ By stopping the activation of the 296 complement system at the stage of C3-convertase formation, CR1 is also indirectly involved in 297 reducing the deposition of sC5b-9, which would have formed afterwards if the complement 298 system had been subsequently activated.

299 *CR1* is expressed by several cell types, including red blood cells (RBC), leukocytes, and 300 among specialized renal cells, CR1 is localized exclusively on glomerular podocytes. The FSGS 301 related variants in CR1 - rs17047661 which was replicated in Latin-American descent 302 individuals and its pair - rs17047660 are known as Knops group polymorphisms and are a part 303 of the Red Cell Surface Antigens, which give rise to the Sl2 and McC^b alleles in the Swain-Langley 304 1 and 2 allele pairs (Sl1/Sl2) and McCoy a and b (McC^a/McC^b), respectively. ²². The K1590E 305 substitution and the R1601G substitution in CR1 are located just 11 amino acids away from 306 each other and are in strong LD for both the 1000 genomes for the global African population

It is made available under a CC-BY 4.0 International license .

307 (r²=0.15, D'=1) and for African-American descent from study data (r²=0.24, D'=1). They are
308 located in the Long Homologous Repeats (LHRs), motif D, which is responsible for C1q and MBL
309 binding.²²

310 No genetic alterations in the adaptive immune system have been identified in FSGS 311 patients to date, and the role of immune and complement systems genetic variants remains 312 unknown. Recent studies have described the role of the complement system in various 313 glomerulopathies.²³ Typically, the reduction in CR1 expression is linked to the severity of the 314 disease, as indicated by the degree of inflammation or tissue damage. ²⁴ Autoantibodies directed 315 against kidney-expressed autoantigens or antibody/antigen complexes deposited in the kidney 316 are causative agents of various human kidney diseases. There are cases of C3-mediated 317 inflammation and deposition. ^{25,26} Further, inhibition of C3 reduces proteinuria in animal 318 models.²⁷ With regard to FSGS, IgG and C3 deposits are often observed in the affected glomeruli, 319 but the pathogenic role of these deposits remains still unclear, and therapy against the 320 complement system has not been studied in FSGS.28

321 Another study has demonstrated elevated levels of Ba, Bb, C4a, and sC5b-9 in the 322 plasma and urine of patients afflicted with primary FSGS. The detection of these protein 323 deposits in the blood signifies that the complement cascade is activated at a site where 324 fragments can gain entry into the vascular space, likely in the mesangial and sclerotic regions. 325 Conversely, the rise in urine Ba, C4a, and sC5b-9 levels in some patients may reflect 326 complement activation in the glomerulus, or alternatively, activation of filtered proteins in the 327 tubular lumen or downstream in the urinary collection system. ²⁹ While C5b-9 complexes 328 generally form directly on the membranes of microorganisms, particularly Gram-negative ones, 329 they can also affect adjacent cells, resulting in "bystander" harm.

The relationship between activation of the classical and alternative pathways in
response to the presence of Knops antigens in *CR1* has been investigated previously, and a
lack of correlation has been noted. However, there is a reasonable discrepancy between

It is made available under a CC-BY 4.0 International license .

333 the results of serological studies of human samples and those obtained from parts of 334 recombinant proteins. Prior investigations have challenged the conjecture that SI2 and 335 McC^b influence the phenotype by modulating the activity of the cofactor implicated in the 336 cleavage of C3b and C4b or the C1q binding activity. ³⁰ Nevertheless, these findings 337 warrant future exploration of the involvement of the lectin pathway in the activation of 338 the complement system. ³¹ For example, the contribution of the lectin pathway in the 339 activation of the complement system may play a crucial role in the development of 340 progressive glomerular damage and long-term urinary abnormalities in patients with 341 Henoch-Schönlein purpura nephritis (HSPN). ³² In the case of FSGS, the presence of MBL 342 deposits that are focal and segmental has been observed, as reported in previous studies, 343 and this can also result in tissue damage, MBL deficiency can lead to autoimmune 344 diseases. 33,34

345 There are many different pathogens that use CR1 as a receptor for cell entry, for 346 example: Leishmania major ³⁵, Legionella pneumophila ³⁶, Leishmania panamensis ³⁷ and 347 *Mycobacterium tuberculosis* ³⁸. It also has been shown that CR1 is a RBC receptor used by 348 Plasmodium falciparum for cell invasion, independent of sialic acid.³⁹ Consistently with this 349 hypothesis, Sl2 (rs17047661) was previously associated with protection against cerebral 350 malaria in sub-Saharan African populations, which resulted in much higher prevalence of Sl2 in 351 African-descent individuals compared to Europeans.¹⁹ In the study conducted by Opi et al, it 352 was noted by the authors that the opposite concomitant effect of the McC^b (rs17047660) allele 353 on the development of severe malaria was of only nominal borderline significance, despite 354 being under significant strong positive selection (iHS<-2.0)¹⁹. At first glance, the association 355 with severe malaria and significant positive McC^b selection are discouraging, but this may 356 explain the linkage of negative and protection haplotypes to each other. Moreover, the authors 357 of the original article tested some haplotypes of SI and McC combinations and found that the 358 combination of Sl2/McC^a alleles has an additive protective effect against malaria, which may 359 explain the lack of replication signal for rs17047660 in the African-American descent.¹⁹

It is made available under a CC-BY 4.0 International license .

360	In conclusion, the findings reported here establish <i>CR1</i> as a novel susceptibility gene for
361	FSGS, involving an autoimmune disease component. Significant alterations in allele frequencies
362	among populations suggest that environmental factors that induce selection pressure, might be
363	responsible for an adaptive benefit, at the cost of kidney disease. These results, together with
364	other evidence of the polygenic nature with many potential mechanisms of FSGS, could be used
365	as a motivation for future GWAS, which would enhance understanding of the molecular genetic
366	mechanisms underlying the disease.

367

368 Data availability

- 369 FSGS cohort allele frequencies and gene burden rare allele counts are available in the
- 370 Supplementary Tables. Raw sequencing data for control cohort subjects are available through

the dbGAP, accession numbers are available in the Supplementary Table 1.

372

373 Author contributions

- 374 R.S., Z.M., J.B.K., C.A.W., M.J.D., A.S., M.A. designed and conceived the study.
- 375 R.S., Z.M., A.L., J.B.K., C.A.W., Al.S., A.S., M.J.D., M.A. analyzed the data
- 376 J.B.K., C.A.W., M.J.D., A.S., M.A. acquired funding

377 N.G., C.S. managed control cohorts

- 378 M.J.D., A.S., M.A. supervised the study
- 379 R.S., J.B.K., C.A.W., M.J.D., A.S., M.A. wrote the manuscript
- 380 All authors reviewed and approved the manuscript

- 382 Acknowledgments. This work was supported in part by the Intramural Research Program,
- 383 NIDDK, NIH (JBK). This project has been funded in part with federal funds from the National

It is made available under a CC-BY 4.0 International license .

384 Cancer Institute, National Institutes of Health, under contract 75N91019D00024. The content 385 of this publication does not necessarily reflect the views or policies of the Department of Health 386 and Human Services, nor does mention of trade names, commercial products, or organizations 387 imply endorsement by the U.S. Government. This Research was supported [in part] by the 388 Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research 389 and NIDDK. The authors acknowledge the contributions of the following investigators who 390 recruited subjects for FSGS genetic studies, published in Kopp et al, Nature Genetics, 2008, as 391 DNA from those subjects was used in the present study. These investigators include Kopp [B, 392 Freedman BI, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, 393 Mokrzycki MH, Schelling JR, Simon E, Trachtman H.

- **394** R.S., Al.S. were supported by the Ministry of Science and Higher Education of the Russian
- **395** Federation (Priority 2030 Federal Academic Leadership Program).
- **396** A.L. was supported by Ministry of Science and Higher Education of the Russian Federation
- **397** (Agreement # 075-15-2022-301).
- 398 M.A. was in part supported by Nationwide Foundation Pediatric Innovation Fund.
- 399

400 Disclosures

- 401 M.J.D. is a founder of Maze Therapeutics; A.S. and Z.M. are employees of Genentech Inc.
- 402 Other authors have no competing interests to disclose.

It is made available under a CC-BY 4.0 International license .

403 References

- 405 1. O'Shaughnessy, M.M., Hogan, S.L., Thompson, B.D., Coppo, R., Fogo, A.B., and Jennette, J.C.
- 406 (2018). Glomerular disease frequencies by race, sex and region: results from the International
- 407 Kidney Biopsy Survey. Nephrol. Dial. Transplant. *33*, 661–669.
- 408 2. Dragovic, D., Rosenstock, J.L., Wahl, S.J., Panagopoulos, G., DeVita, M.V., and Michelis, M.F.
- 409 (2005). Increasing incidence of focal segmental glomerulosclerosis and an examination of
- 410 demographic patterns. Clin. Nephrol. *63*, 1–7.
- 411 3. Shabaka, A., Tato Ribera, A., and Fernández-Juárez, G. (2020). Focal Segmental
- 412 Glomerulosclerosis: State-of-the-Art and Clinical Perspective. Nephron *144*, 413–427.
- 413 4. Kitiyakara, C., Kopp, J.B., and Eggers, P. (2003). Trends in the epidemiology of focal segmental
 414 glomerulosclerosis. Semin. Nephrol. *23*, 172–182.
- 415 5. Yu, H., Artomov, M., Brähler, S., Stander, M.C., Shamsan, G., Sampson, M.G., White, J.M., Kretzler,
- 416 M., Miner, J.H., Jain, S., et al. (2016). A role for genetic susceptibility in sporadic focal segmental
 417 glomerulosclerosis. J. Clin. Invest. *126*, 1067–1078.
- 418 6. Kopp, J.B., Nelson, G.W., Sampath, K., Johnson, R.C., Genovese, G., An, P., Friedman, D., Briggs,
- 419 W., Dart, R., Korbet, S., et al. (2011). APOL1 genetic variants in focal segmental
- 420 glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129–2137.
- 421 7. Kopp, J.B., Smith, M.W., Nelson, G.W., Johnson, R.C., Freedman, B.I., Bowden, D.W., Oleksyk, T.,
- 422 McKenzie, L.M., Kajiyama, H., Ahuja, T.S., et al. (2008). MYH9 is a major-effect risk gene for focal
- 423 segmental glomerulosclerosis. Nat. Genet. *40*, 1175–1184.
- 424 8. Kao, W.H.L., Klag, M.J., Meoni, L.A., Reich, D., Berthier-Schaad, Y., Li, M., Coresh, J., Patterson, N.,
- Tandon, A., Powe, N.R., et al. (2008). MYH9 is associated with nondiabetic end-stage renal
 disease in African Americans. Nat. Genet. *40*, 1185–1192.
- 427 9. Genovese, G., Friedman, D.J., Ross, M.D., Lecordier, L., Uzureau, P., Freedman, B.I., Bowden,
- 428 D.W., Langefeld, C.D., Oleksyk, T.K., Uscinski Knob, A.L., et al. (2010). Association of trypanolytic
 429 ApoL1 variants with kidney disease in African Americans. Science *329*, 841–845.
- 430 10. Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., Del Angel, G., Levy-Moonshine, A.,
- 431 Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013). From FastQ data to high confidence
- 432 variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics
- **433** *11*, 11.10.1-11.10.33.
- **434 11**. Hail Team. Hail 0.2.
- 435 12. Athey, T.L., Liu, T., Pedigo, B.D., and Vogelstein, J.T. (2019). AutoGMM: Automatic and
 436 Hierarchical Gaussian Mixture Modeling in Python. ArXiv.
- 437 13. Ho, D.E., Imai, K., King, G., and Stuart, E.A. (2011). MatchIt²: Nonparametric Preprocessing
 438 for Parametric Causal Inference. J. Stat. Softw. 42,.
- 439 14. Wang, M., Chun, J., Genovese, G., Knob, A.U., Benjamin, A., Wilkins, M.S., Friedman, D.J., Appel,
- 440 G.B., Lifton, R.P., Mane, S., et al. (2019). Contributions of rare gene variants to familial and
- 441 sporadic FSGS. J. Am. Soc. Nephrol. *30*, 1625–1640.
- 442 15. Edmonson, M.N., Patel, A.N., Hedges, D.J., Wang, Z., Rampersaud, E., Kesserwan, C.A., Zhou, X.,

- 443 Liu, Y., Newman, S., Rusch, M.C., et al. (2019). Pediatric Cancer Variant Pathogenicity 444 Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline 445 variants. Genome Res. 29, 1555-1565. 446 16. Chennen, K., Weber, T., Lornage, X., Kress, A., Böhm, J., Thompson, J., Laporte, J., and Poch, O. 447 (2020). MISTIC: A prediction tool to reveal disease-relevant deleterious missense variants. PLoS 448 ONE 15, e0236962. 449 17. Samocha, K.E., Kosmicki, J.A., Karczewski, K.I., O'Donnell-Luria, A.H., Pierce-Hoffman, E., 450 MacArthur, D.G., Neale, B.M., and Daly, M.J. (2017). Regional missense constraint improves 451 variant deleteriousness prediction. BioRxiv. 452 18. Lee, S., Abecasis, G.R., Boehnke, M., and Lin, X. (2014). Rare-variant association analysis: 453 study designs and statistical tests. Am. J. Hum. Genet. 95, 5-23. 454 19. Opi, D.H., Swann, O., Macharia, A., Uyoga, S., Band, G., Ndila, C.M., Harrison, E.M., Thera, M.A., 455 Kone, A.K., Diallo, D.A., et al. (2018). Two complement receptor one alleles have opposing 456 associations with cerebral malaria and interact with α +thalassaemia. ELife 7,. 457 20. Freiwald, T., and Afzali, B. (2021). Renal diseases and the role of complement: Linking 458 complement to immune effector pathways and therapeutics. Adv. Immunol. 152, 1–81. 459 21. Poppelaars, F., and Thurman, J.M. (2020). Complement-mediated kidney diseases. Mol. 460 Immunol. 128, 175-187. 461 22. Moulds, J.M. (2010). The Knops blood-group system: a review. Immunohematology 26, 2–7. 462 23. Mathern, D.R., and Heeger, P.S. (2015). Molecules great and small: the complement system. 463 Clin. J. Am. Soc. Nephrol. 10, 1636-1650. 464 24. Moll, S., Miot, S., Sadallah, S., Gudat, F., Mihatsch, M.J., and Schifferli, J.A. (2001). No 465 complement receptor 1 stumps on podocytes in human glomerulopathies. Kidney Int. 59, 160-466 168. 467 25. Willows, J., Wood, K., Bourne, H., and Sayer, J.A. (2019). Acquired C1-inhibitor deficiency 468 presenting with nephrotic syndrome. BMJ Case Rep. 12,. 469 26. Sethi, S., Fervenza, F.C., Zhang, Y., Zand, L., Vrana, J.A., Nasr, S.H., Theis, J.D., Dogan, A., and 470 Smith, R.J.H. (2012). C3 glomerulonephritis: clinicopathological findings, complement 471 abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 82, 465-473. 472 27. Salant, D.J., Belok, S., Madaio, M.P., and Couser, W.G. (1980). A new role for complement in 473 experimental membranous nephropathy in rats. J. Clin. Invest. 66, 1339–1350. 474 28. Strassheim, D., Renner, B., Panzer, S., Fuquay, R., Kulik, L., Ljubanović, D., Holers, V.M., and 475 Thurman, J.M. (2013). IgM contributes to glomerular injury in FSGS. J. Am. Soc. Nephrol. 24, 476 393-406. 477 29. Thurman, J.M., Wong, M., Renner, B., Frazer-Abel, A., Giclas, P.C., Joy, M.S., Jalal, D., Radeva, 478 M.K., Gassman, J., Gipson, D.S., et al. (2015). Complement Activation in Patients with Focal 479 Segmental Glomerulosclerosis. PLoS ONE 10, e0136558. 480 30. Tetteh-Quarcoo, P.B., Schmidt, C.Q., Tham, W.-H., Hauhart, R., Mertens, H.D.T., Rowe, A., 481 Atkinson, J.P., Cowman, A.F., Rowe, J.A., and Barlow, P.N. (2012). Lack of evidence from studies 482 of soluble protein fragments that Knops blood group polymorphisms in complement receptor-
- **483** type 1 are driven by malaria. PLoS ONE *7*, e34820.

It is made available under a CC-BY 4.0 International license .

- 484 31. Ghiran, I., Barbashov, S.F., Klickstein, L.B., Tas, S.W., Jensenius, J.C., and Nicholson-Weller, A.
- (2000). Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 192,
 1797–1808.
- 487 32. Roos, A., Rastaldi, M.P., Calvaresi, N., Oortwijn, B.D., Schlagwein, N., van Gijlswijk-Janssen,
- 488 D.J., Stahl, G.L., Matsushita, M., Fujita, T., van Kooten, C., et al. (2006). Glomerular activation of
- the lectin pathway of complement in IgA nephropathy is associated with more severe renal
 disease. J. Am. Soc. Nephrol. *17*, 1724–1734.
- 491 33. Lhotta, K., Würzner, R., and König, P. (1999). Glomerular deposition of mannose-binding
 492 lectin in human glomerulonephritis. Nephrol. Dial. Transplant. *14*, 881–886.
- 493 34. Tsutsumi, A., Takahashi, R., and Sumida, T. (2005). Mannose binding lectin: genetics and
 494 autoimmune disease. Autoimmun. Rev. *4*, 364–372.
- 495 35. Da Silva, R.P., Hall, B.F., Joiner, K.A., and Sacks, D.L. (1989). CR1, the C3b receptor, mediates
- 496 binding of infective Leishmania major metacyclic promastigotes to human macrophages. J.
 497 Immunol. 143, 617–622.
- 498 36. Payne, N.R., and Horwitz, M.A. (1987). Phagocytosis of Legionella pneumophila is mediated
 499 by human monocyte complement receptors. J. Exp. Med. *166*, 1377–1389.
- 500 37. Robledo, S., Wozencraft, A., Valencia, A.Z., and Saravia, N. (1994). Human monocyte infection
- 501 by Leishmania (Viannia) panamensis. Role of complement receptors and correlation of
- susceptibility in vitro with clinical phenotype. J. Immunol. *152*, 1265–1276.
- 503 38. Schlesinger, L.S., Bellinger-Kawahara, C.G., Payne, N.R., and Horwitz, M.A. (1990).
- 504 Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement
- receptors and complement component C3. J. Immunol. *144*, 2771–2780.
- 39. Tham, W.-H., Wilson, D.W., Lopaticki, S., Schmidt, C.Q., Tetteh-Quarcoo, P.B., Barlow, P.N.,
 Richard, D., Corbin, J.E., Beeson, J.G., and Cowman, A.F. (2010). Complement receptor 1 is the
 host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci
 USA 107, 17327–17332.
- 510

511 Figure Captions

- 512 Figure 1. Study design, principal component analysis, and quantile-quantile plots to
- 513 identify calibration of synonymous variants between case and control cohorts.
- 514 (A) **Case-control study design**. DNA samples from FSGS cases and controls were
- 515 examined for coding variants in a podocyte exome panel gene panel composed of 2482
- 516 genes and also was subjected to whole exome analysis.
- 517 (B) **Principal component analysis** illustrates case-control matching in European-
- 518 derived, African-derived and Latin-American-derived-populations and demonstrates
- 519 genetic segregation of these three populations.

It is made available under a CC-BY 4.0 International license .

520 (C) Quantile-quantile (QQ)-plots for the association study of the common

521 synonymous variants with gnomAD population specific allele frequency ≥ 0.01).

- 522 These plots illustrate case-control matching quality for the European-derived (left),
- 523 African-derived (middle), Latin-American-derived (right) populations. The test lambda-
- 524 GC (genomic inflation factor) for genome-wide association studies (GWAS) compares the
- 525 median test statistic against the expected median test statistic under the null hypothesis,
- 526 in which there is no association for each variant. This test identifies systemic biases and
- 527 significant associations. Here, most of the points fall along the diagonal, indicating the
- **528** absence of systemic bias.
- 529 Abbreviations. EUR, European-Americans. AFR, African-Americans. AMR, Admixture
- 530 Americans

It is made available under a CC-BY 4.0 International license .

532 Figure 2. Rare variant association study in the European-American cohort and

533 replication of CR1 and APOL1 variants in the Admixed American cohort.

- 534(A) Shown graphically are the results of rare-variant association study involving the
- 535 European-American subject cluster (gnomAD EUR AF < 0.01; missense and PTV (protein
- truncating variants). Statistical approaches included the following: the Simes method
- 537 for multiple hypothesis testing, the Fisher exact test for testing two groups, C-alpha test
- 538 for comparing the variance of each group against the expected, adaptive sum statistic
- 539 (ASUM) for testing variants; , weighted sum statistics (WSS) for testing variants and
- 540 kernel-based adaptive clustering (KBAC) for variant classification and association
- testing. Of the top 10 (most significant) genes, four with known FSGS-associated variants.
- 542 *CR1*, complement C3b/C4B receptor 1; *KANK1*, KN motif and ankyrin repeat domains 1;
- 543 *COL4A4*, collagen type 4, alpha 4 chain; IL-36G, interleukin 36G.

544

545 (B) Shown are associations of FSGS-related SNPs in *CR1* and *APOL1* in the GnomAD aggregation

- 546 database population among European-Americans (top panels) and Admixed-Americans
- 547 (bottom panels). Left Panels. Two rare variants in *CR1* have been associated with FSGS in
- 548 Euro-Americans, and one of these variants in CR1 has also been associated with FSGS in Latin-
- 549 Americans (both variants in *CR1* are common in Latin-Americans). **Right panels**. Two rare
- variants in *APOL1* are associated with FSGS in European-Americans and in Latin-Americans.



